Skip to main content
. Author manuscript; available in PMC: 2012 Dec 28.
Published in final edited form as: Oncogene. 2011 Oct 17;31(26):3164–3176. doi: 10.1038/onc.2011.480

Figure 4. NF-κB functions as a specific tumor promoter and enhances tumorigenesis in a resistant mouse strain.

Figure 4

A) Bioluminescent detection of NF-κB activity in the lungs of NF-κB reporter mice after a single IP injection of MCA (15 μg/g) or BHT (200 μg/g) (n=3 for MCA and 4 for BHT, *=p<0.05 compared to baseline and MCA). B) Lung surface tumor counts in WT and IKTA mice treated with a single IP injection of MCA (15 μg/g) ± 8 weekly IP injections of BHT (200 μg/g) or vehicle (corn oil) control ± doxycycline (dox) treatment from week -2–16. Mice were sacrificed at 16 weeks after MCA treatment (n=6–8 mice per group, *=p<0.01 compared to MCA treatment alone). C) Lung surface tumor counts in WT (C57BL/6) mice and IKTA mice (C57BL/6 background) treated with dox for 6 months after a single IP injection of urethane (n=10–11 per group, p<0.05).